TILT Biotherapeutics Ltd is a clinical stage company working in the area of enabling tumor T-cell therapy and checkpoint inhibitors with oncolytic viruses. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy. The TILT approach has the potential to achieve similar results in CAR-T therapy of solid tumors as currently achieved for CD19+ hematological tumors.
TILT was founded by Pr. Akseli Hemminki, who has published hundreds of papers in the field and treated almost 300 patients with 10 different oncolytic viruses. In 2013 Pr. Hemminki started his second company, TILT Biotherapeutics, which technology is based on his past findings in the lab, and more importantly in the clinic. The research conducted by TILT alone or in collaboration with some of world’s leading research groups with synergic technologies has generated very good results. The lead candidate is a clinical stage TNFα/IL2 armed oncolytic adenovirus (TILT-123 or Ad5/3-E2F-delta24-hTNFα-IRES-hIL2). The first trial will take place in Europe and address metastatic melanoma in combination with TILs. Additional trials in other solid tumor indications are planned in combination with a checkpoint modulator and a CAR-T product.
For contact: aino (at) tiltbio.com
TILT was founded by Pr. Akseli Hemminki, who has published hundreds of papers in the field and treated almost 300 patients with 10 different oncolytic viruses. In 2013 Pr. Hemminki started his second company, TILT Biotherapeutics, which technology is based on his past findings in the lab, and more importantly in the clinic. The research conducted by TILT alone or in collaboration with some of world’s leading research groups with synergic technologies has generated very good results. The lead candidate is a clinical stage TNFα/IL2 armed oncolytic adenovirus (TILT-123 or Ad5/3-E2F-delta24-hTNFα-IRES-hIL2). The first trial will take place in Europe and address metastatic melanoma in combination with TILs. Additional trials in other solid tumor indications are planned in combination with a checkpoint modulator and a CAR-T product.
For contact: aino (at) tiltbio.com
Location: Finland, Mainland Finland, Helsinki
Employees: 11-50
Total raised: $70.6M
Founded date: 2013
Investors 1
Funding Rounds 5
| Date | Series | Amount | Investors |
| 13.05.2025 | Series B | $25M | - |
| 09.02.2023 | - | $23.71M | - |
| 17.06.2022 | - | $10.7M | - |
| 16.06.2020 | - | $6.99M | - |
| 14.12.2016 | - | $4.21M | - |
Mentions in press and media 15
| Date | Title | Description |
| 21.12.2025 | T-CURX Secures $20M Series A to Advance Non-Viral CAR-T Cancer Therapies | German biotech T-CURX closed a $20 million Series A funding round. The Würzburg-based company will accelerate clinical development of its non-viral CAR-T cell therapies. These innovative treatments target acute myeloid leukemia (AML) and so... |
| 17.12.2025 | German startup T-CURX secures €17.7 million to support development of new cancer treatments | Würzburg-based T-CURX today announces the first closing of a €17.7 million Series A to accelerate clinical development of T-CURX non-viral clinical CAR-T therapies in AML and solid tumor indications, as well as advancing T-CURX proprietary ... |
| 13.05.2025 | Tilt Biotherapeutics Closes USD25M Series B Financing | Tilt Biotherapeutics, a Helsinki, Finland-based clinical-stage biotechnology company developing intravenously delivered cancer immunotherapies, raised USD25M in Series B funding. The round was led by European Innovation Council (EIC) Fund, ... |
| 13.05.2025 | Finnish startup Tilt Biotherapeutics moves closer to immune-oncology breakthrough with fresh €22.6 million | Helsinki-based TILT Biotherapeutics (Tiltbio), a clinical-stage BioTech company developing intravenously delivered cancer immunotherapies, announced today it has raised €22.6 million in a Series B financing. The financing was supported by e... |
| 04.07.2024 | Finland: Sustainability and innovation for shaping global technology trends | Fueled by a combination of world-class education, a strong culture of research and development, and government support, Finland has cultivated a dynamic environment for startups and established tech companies alike. From pioneering advancem... |
| 14.02.2024 | TILT Biotherapeutics Awarded USD 2M Grant from US Department of Defense for Ovarian Cancer Immunotherapy Research | - |
| 09.02.2023 | Finnish TILT Biotherapeutics closes €22M financing round | Finnish TILT Biotherapeutics closes €22M financing round 09 February, 2023, 14:32 Rostyslav Sobachynskyi --> --> --> -->--> --> --> --> --> --> --> --> --> Helsinki-based TILT Biotherapeutics has an... |
| 07.02.2023 | TILT Biotherapeutics Closes €22M Financing Round | TILT Biotherapeutics, a Helsinki, Finland-based clinical-stage biotechnology company developing cancer immunotherapies, raised €22M in funding. The round was led by Lifeline Ventures. The company intends to use the funds to advance to Phase... |
| 17.06.2022 | Finland’s TILT Biotherapeutics raises €10M for cancer treatment | Finland’s TILT Biotherapeutics raises €10M for cancer treatment 17 June, 2022, 16:41 Rostyslav Sobachynskyi --> --> --> -->--> --> --> --> --> --> --> --> --> The Helsinki-based TILT Biotherapeutics... |
| 14.06.2022 | Tilt Biotherapeutics Raises $10.7M in Funding | Tilt Biotherapeutics, a Helsinki, Finland-based clinical-stage biotechnology company, raised $10.7M in funding. The round was led by Lifeline Ventures with participation from Tesi. The company also announces the appointment of Dr. Tuija Kei... |
Show more